Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false' Novo Nordisk, maker of the popular medications Ozempic and Wegovy, filed a lawsuit Tuesday against the pharmaceutical company Eli Lilly, accusing it of making deceptive advertising claims about its weight-loss drug Zepbound
Some people endure them, while others experience symptoms severe enough to discontinue treatment
While the safety of GLP-1 RAs is well established, current scientific evidence on the efficacy of microdosing GLP-1 RAs is lacking and further research is required to assess its benefits at lower doses
Any oral product claiming to be retatrutide should be viewed with extreme skepticism
Dulaglutide causes thyroid C-cell tumors in rats
Stimulates pulsatile growth-hormone release without significant effect on ACTH, cortisol, or prolactin in published models the basis for its selective GHRP classification